Exclusive Video Q&A With Sijmen de Vries, CEO of Pharming
(firmenpresse) - LOS ANGELES, CA -- (Marketwire) -- 04/04/12 -- Trading on the Euronext, Pharming Group NV (EURONEXT: PHARM) produces, purifies and formulates recombinant human proteins using its transgenic technology platform for therapeutic indications in Hereditary Angioedema, Transplant Rejection, Blood Coagulation Disorders and Ischemic Reperfusion Injury.
Pharming Group develops products for various applications in humans. Its product areas include: biopharmaceuticals, biomaterials and bionutritionals. Its product portfolio includes its Rhucinr, a recombinant human C1 esterase inhibitor, is being developed as a replacement therapy for patients who suffer from hereditary angioedema (HAE). Late last month, the company announced that it has entered into an agreement with Hyupjin Corporation, to commercialize RUCONEST for the treatment of acute attacks of Hereditary Angioedema (HAE) in the Republic of Korea.
The firm's innovative therapeutics for the treatment of genetic disorders and ageing diseases, as well as specialty products for surgical indications, and intermediates for nutritional products and a variety of other applications are preparing to enter humans after some impressive results in pre-clinical studies. Despite being early in their development pipeline, they have several partnerships and collaborations with Swedish Orphan Biovitrum AB, GTC Biotherapeutics Inc, AgResearch, Eczacibasi Ilac, Pazarlama, Esteve, NovaThera, Schering-Plough, Aslan, and even the US Army.
Sijmen de Vries, the Chief Executive Officer of the company, recently sat down with BioMedReports to discuss the firm's truly innovative technology platform which involves a recombinant human C1 esterase inhibitor obtained from the milk of transgenic rabbits.
Dr de Vries, MD, MBA, is responsible for the overall management of the company -- which is still early in their development process. Dr de Vries has extensive senior level experience in both the pharmaceutical and biotechnology industries. He joins Pharming from Swiss-based 4-Antibody where he was CEO. Dr de Vries has also been CEO of Morphochem and prior to this spent many years at Novartis and at SmithKline Beecham Pharmaceuticals where he held senior business and commercial positions. Dr de Vries also holds non-executive directorships in two private life science companies. Dr de Vries holds a Medical Degree from the University of Amsterdam and a MBA in General Management from Ashridge Management College (UK).
His exclusive interview can be seen below.
The full video interview with Dr. Sijmen de Vries, CEO of Pharming Group is now available at:
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:
News developments and live healthcare sector updates are available constantly via twitter at:
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biomedical news and the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. They sell a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release is available at BioMedReports.Com.
Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail:
Tel: +1 323 472 4480
Fax: +1 888 210 3556
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2012 - 11:53 Uhr
Sprache: Deutsch
News-ID 131981
Anzahl Zeichen: 0
contact information:
Town:
LOS ANGELES, CA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 308 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Exclusive Video Q&A With Sijmen de Vries, CEO of Pharming"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMedReports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
